Shenogen Announces a New Member to Scientific Advisory Board: Dr. Yan Sun
June 3rd, 2015, Beijing, China
Shenogen Pharma Group announces the addition of Dr. Yan Sun to its Scientific Advisory Board (SAB). Dr. Yan Sun, Academician of Chinese Academy of Engineering, is a pioneer of Chinese medical oncology.
“We are delighted to welcome Dr. Sun to our SAB.” said Dr. Kun Meng, Chairman & CEO of Shenogen. “Dr. Sun is the principal investigator of our icaritin phase II study. He has more than 50-year experience and significant contribution to cancer medicine developing, cancer clinical treatment especially testicular cancer, lymphoma and lung cancer, traditional Chinese medicine treatment in immunity disease, as well as education and healthcare. We are sure that his advice will be helpful for us making better decision of development direction and future strategy.”
Dr. Sun regards Shenogen as to be a leading biopharma company in China with innovative technology and cancer target. He appreciates the encouraging clinical results of icaritin and hopes to help in promoting more efficient targeted drugs for cancer treatment.
Dr.Sun graduated from Peking University and got PhD degree in Peking Union Medical College. He started working in Cancer Hospital, Chinese Academy of Medical Sciences since 1959. He was visiting professor in M.D. Anderson Cancer Center in 1979-1981. Dr. Sun is Director of National Drug Clinical Research Center (Oncology), Professor of Peking Union Medical College (PUMC), Vice President of Asian Clinical Oncology Society (ACOS) and Cancer Foundation of China (CFC). He has authored/co-authored 25 books and more than 300 papers.
Dr. Sun joins Drs. Michael Karin, Douglas Hanahan, V. Craig Jordan, Robert N. Eisenman and Changxiao Liu who are currently members of Shenogen’s Scientific Advisory Board.
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.